buy Prozac




Arthritis
Genital Warts
Osteoporosis
Parasites




Prozac
Analytical methods for the quality control of Prozac capsules.

Raggi MA, Bugamelli F, Casamenti G, Mandrioli R, De Ronchi D, Volterra V.

Department of Pharmaceutical Sciences, University of Bologna, Italy. raggima kaiser.alma.unibo.it

Some analytical methods (two spectrophotometric and two chromatographic procedures) for the determination of fluoxetine in Prozac capsules are described. All of them are applied to the samples after extracting the drug with a methanol water mixture. The direct and derivative spectrophotometric methods are simple and reliable; the derivative method gives better recovery and lessens interference. Both methods show linearity in the 5-30 microg ml(-1) range of the fluoxetine concentration range. Both HPLC methods (spectrophotometric and spectrofluorimetric detection) use a tetramethylammonium perchlorate buffer-acetonitrile mixture as the mobile phase and a C8 reversed phase column. The UV detection is performed at 226 nm, while the fluorimetric detection is performed by exciting at 230 nm and revealing the emission at 290 nm. The HPLC method with UV detection is more precise, but the procedure with fluorimetric detection is more sensitive.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9919971&dopt=Abstract fluoxetine Prozac



Prozac
Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology.

Reeve HL, Nelson DP, Archer SL, Weir EK.

Department of Physiology, University of Alberta, Edmonton, Canada T6G 2R7.

The anorexic agents dexfenfluramine and fenfluramine plus phentermine have been associated with outbreaks of pulmonary hypertension. The fenfluramines release serotonin and reduce serotonin reuptake in neurons. They also inhibit potassium current (IK), causing membrane potential depolarization in pulmonary arterial smooth muscle cells. The recent withdrawal of the fenfluramines has led to the use of fluoxetine and phentermine as an alternative anorexic combination. Because fluoxetine and venlafaxine reduce serotonin reuptake, we compared the effects of these agents with those of phentermine and dexfenfluramine on pulmonary arterial pressure, IK, and membrane potential. Fluoxetine, venlafaxine, and phentermine caused minimal increases in pulmonary arterial pressure at concentrations < 100 microM but did cause a dose-dependent inhibition of IK. The order of potency for inhibition of IK at +50 mV was fluoxetine > dexfenfluramine = venlafaxine > phentermine. Despite the inhibitory effect on IK at more positive membrane potentials, fluoxetine, venlafaxine, and phentermine, in contrast to dexfenfluramine, had minimal effects on the cell resting membrane potential (all at a concentration of 100 microM). However, application of 100 microM fluoxetine to cells that had been depolarized to -30 mV by current injection elicited a further depolarization of >18 mV. These results suggest that fluoxetine, venlafaxine, and phentermine do not inhibit IK at the resting membrane potential. Consequently, they may present less risk of inducing pulmonary hypertension than the fenfluramines, at least by mechanisms involving membrane depolarization.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9950882&dopt=Abstract fluoxetine Prozac



Prozac
Hyperglycemia induced by acute central fluoxetine administration: role of the central CRH system and 5-HT3 receptors.

Carvalho F, Barros D, Silva J, Rezende E, Soares M, Fregoneze J, De Castro e Silva E.

Life Sciences Department, Bahia State University, 41195-001 Salvador, Bahia, Brazil.

Brain serotonin and CRH systems participate in the control of blood glucose levels. We have previously demonstrated that the pharmacological stimulation of central 5-HT3 receptors, the target for several therapeutic agents used as antiemetics in the course of chemotherapy, induces hyperglycemia. The aim of the present study was to investigate the participation of the brain CRH component and 5-HT3 receptors in basal blood glucose levels as well as in the hyperglycemia induced by third ventricle injections of fluoxetine, a serotonin reuptake inhibitor with a broad range of clinical use. In this study, we used fasted adult Wistar male rats (220 +/- 20 g) whose third ventricles were cannulated 7 days prior to the experiments. Acute third ventricle injections of fluoxetine caused a significant increase in plasma glucose levels throughout the experiment. Pretreatment with alpha-helical CRH, a selective CRH antagonist, significantly blunted fluoxetine-induced hyperglycemia. Also, pretreatment with two distinct selective 5-HT3 receptor antagonists (LY-278,584 and ondansetron) significantly impaired the rise in plasma glucose levels observed in fluoxetine-treated animals pretreated with isotonic saline solution. None of these antagonists was able to modify blood glucose levels when injected alone into the third ventricle. Animals receiving third ventricle injections of fluoxetine, in spite of being hyperglycemic, presented plasma insulin levels similar to those displayed by normoglycemic, saline-treated controls. It is suggested that the acute increase in brain serotonergic activity caused by third ventricle injections of fluoxetine induces a hyperglycemic response that requires the functional integrity of the brain CRH system and 5-HT3 receptors. Also, it is proposed that the absence of a compensatory increase in plasma insulin levels may contribute to the generation of a hyperglycemic response after central fluoxetine administration.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15223272&dopt=Abstract fluoxetine Prozac



Prozac
Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.

Ramasubbu R.

Department of Psychiatry, University of Ottawa, Ont. RRamasub rohcg.on.ca

OBJECTIVE: To determine the efficacy of substituting moclobemide, a reversible monoamine oxidase-A inhibitor, for fluoxetine to reverse fluoxetine-induced sexual dysfunction in patients with depression. DESIGN: Prospective open trial. SETTING: Outpatient treatment. PARTICIPANTS: Five patients with depressive disorder who experienced sexual side effects during treatment with standard doses of fluoxetine (20 to 40 mg per day). INTERVENTION: Discontinuation of fluoxetine and replacement with moclobemide (300 to 600 mg per day) after a 2-week washout period. OUTCOME MEASURES: Libido, orgasmic function (in women) or erectile and ejaculatory function (in men), and overall improvement in sexual function during a follow-up period of 2 months to 3 years. RESULTS: Among patients receiving fluoxetine questioned about sexual side effects, 4 (1 man and 3 women) had treatment-related diminished libido with poor orgasmic response or partial erectile failure, and 1 female patient had enhanced sexual desire with intense clitoral stimulation. In all patients, sexual disturbances resolved completely after a 2-week washout period and a switch to treatment with moclobemide. Moclobemide was well tolerated. The antidepressant effect of moclobemide was comparable to that of fluoxetine. CONCLUSIONS: Moclobemide may be preferred as a treatment for depression in patients with fluoxetine-induced sexual dysfunction.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9987207&dopt=Abstract fluoxetine Prozac



Prozac
Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells.

Choi JS, Choi BH, Ahn HS, Kim MJ, Rhie DJ, Yoon SH, Min do S, Jo YH, Kim MS, Sung KW, Hahn SJ.

Department of Physiology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Socho-gu, Seoul 137-701, South Korea.

The effect of fluoxetine (Prozac) on 5-hydroxytryptamine(3) (5-HT(3))-mediated currents in NCB-20 neuroblastoma cells was examined using the whole-cell patch-clamp technique. Fluoxetine produced a significant reduction of peak amplitude without altering the activation time course of 5-HT(3)-mediated currents. These effects were concentration-dependent, with an IC(50) value of 4.15 microM. No voltage dependence was evident in fluoxetine's block of 5-HT(3)-mediated currents over the entire voltage range tested. The extent of block by pre-application of fluoxetine was significantly greater than that by co-application. Fluoxetine also increased the apparent rate of current desensitization to 5-HT application. Using a first-order kinetics analysis, the open-channel blocking rate constants were 0.06 microM(-1)s(-1) (k(+1), association rate constant) and 0.05 s(-1) (k(-1), dissociation rate constant), with an apparent K(d) (=k(-1)/k(+1)) of 0.83 microM. This value is close to an IC(50) of 1.11 microM obtained from the reduction in tau, the time constant of desensitization. Intracellular application of fluoxetine for long durations had no effect on the amplitude or kinetics of 5-HT(3)-mediated currents. Similarly, norfluoxetine, the major metabolite of fluoxetine, reduced the peak current, and enhanced the rate of current desensitization in a concentration-dependent manner with an IC(50) of 2.66 microM, indicating that norfluoxetine is more potent than fluoxetine in blocking 5-HT(3)-mediated currents. These results indicate that, at clinically relevant concentrations, fluoxetine and its metabolite, norfluoxetine, block 5-HT(3)-mediated currents in NCB-20 neuroblastoma cells.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14609737&dopt=Abstract fluoxetine Prozac



Prozac
Fluoxetine and sertraline stimulate gastric acid secretion via a vagal pathway in anaesthetised rats.

Abdel Salam OM.

Department of Pharmacology, National Research Centre, Tahrir St., Dokki, Cairo, Egypt. omasalam hotmail.com

The effect of the selective serotonin reuptake inhibitors, fluoxetine and sertraline on basal, secretagogues (histamine or bethanechol)- and distention-stimulated gastric acid secretion was investigated in the urethane-anaesthetised acute gastric fistula rat. Gastric acid secretion was measured by flushing of the gastric contents with saline every 15 min. Fluoxetine (10 or 20 mg kg(-1), i.p.) produced a dose-dependent increase in basal gastric acid secretion. These stimulatory effects were abolished by vagotomy. Intraperitoneally administered sertraline also stimulated gastric acid secretion. The stimulatory effect of lower doses (5 mg kg(-1)) of sertraline was similar to that of the higher (30 mg kg(-1)) doses. The gastric secretory response to i.p. sertraline was long lasting (greater than 60 min), and blocked by vagotomy. Intraperitoneally administered fluoxetine (10 or 20 mg kg(-1)) or sertraline (5 mg kg(-1)) also increased gastric secretion induced by histamine, bethanechol or distention. The fluoxetine or sertraline stimulatory effects of histamine-induced acid secretion were abolished by vagotomy. Data indicate a stimulatory effect for fluoxetine and sertraline mediated by vagal nerve on gastric acid secretion in urethane-anaesthetised rats.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15225675&dopt=Abstract fluoxetine Prozac



Prozac
Adsorption of fluoxetine HCl by activated charcoal.

Cooney DO, Thomason R.

Department of Chemical Engineering, University of Wyoming, Laramie 82071, USA.

We studied the adsorption of fluoxetine HCl (Prozac) by Norit USP XXIII activated charcoal in vitro, in simulated gastric fluid (USP; pH 1.2), and in simulated intestinal fluid (USP; pH 7.5). The data were fitted to both Langmuir and Freundlich equations. The Langmuir Qm values (maximal adsorption capacities) for pH 1.2 and 7.5 were 0.258 and 0.330 g drug/g charcoal, respectively. These excellent capacities suggest that oral charcoal therapy would be effective for fluoxetine overdose.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9145393&dopt=Abstract fluoxetine Prozac



Prozac
Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus.

Ordway GA, Szebeni K.

Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS 39216, USA. gordway psychiatry.umsmed.edu

Repeated treatment of rats with antidepressant drugs down-regulates tyrosine hydroxylase (TH) in the locus coeruleus (LC). Using this effect as a model system, this study evaluated the antidepressant potential of the atypical antipsychotic drug, olanzapine. In an initial study, rats were treated i.p. with saline, olanzapine (3 mg/kg), or imipramine (15 mg/kg) once daily for 18 d. Three additional groups of rats received the same treatments that were overlapped with reserpine administration (0.5 mg/kg.d for 21 d). In a second study, groups of rats were treated twice daily with saline, olanzapine (5 mg/kg.d), fluoxetine (15 mg/kg.d), or fluoxetine (15 mg/kg.d) plus olanzapine (5 mg/kg.d) for 1, 6, 12 and 18 d. In the initial study, imipramine produced a 45% reduction in LC TH levels, while olanzapine had no effect. In reserpinized rats, olanzapine exhibited an action that was opposite to that of imipramine, although this effect did not reach statistical significance. In the second study, olanzapine treatment alone or in combination with fluoxetine up-regulated TH in the LC, while fluoxetine alone had no effect. When fluoxetine was co-administered, olanzapine-induced increases in LC TH were more robust and occurred earlier in the time-course of treatment. Based on this preclinical model alone, olanzapine did not exhibit typical antidepressant properties. The unique effect of olanzapine to elevate LC TH may result from olanzapine-induced increases in LC activity. Such an action may contribute to novel behavioural effects of this atypical antipsychotic drug, including enhanced attention.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15228643&dopt=Abstract fluoxetine Prozac









Prozac or fluoxetine References

Prozac or fluoxetine 1 | Prozac or fluoxetine 2 | Prozac or fluoxetine 3 | Prozac or fluoxetine 4 | Prozac or fluoxetine 5 | Prozac or fluoxetine 6 | Prozac or fluoxetine 7 | Prozac or fluoxetine 8 | Prozac or fluoxetine 9 | Prozac or fluoxetine 10 | Prozac or fluoxetine 11 | Prozac or fluoxetine 12 | Prozac or fluoxetine 13 | Prozac or fluoxetine 14 | Prozac or fluoxetine 15 | Prozac or fluoxetine 16 | Prozac or fluoxetine 17 | Prozac or fluoxetine 18 | Prozac or fluoxetine 19 | Prozac or fluoxetine 20 | Prozac or fluoxetine 21 | Prozac or fluoxetine 22 | Prozac or fluoxetine 23 | Prozac or fluoxetine 24 | Prozac or fluoxetine 25 | Prozac or fluoxetine 26 | Prozac or fluoxetine 27 | Prozac or fluoxetine 28 | Prozac or fluoxetine 29 | Prozac or fluoxetine 30 | Prozac or fluoxetine 31 | Prozac or fluoxetine 32 | Prozac or fluoxetine 33 | Prozac or fluoxetine 34 | Prozac or fluoxetine 35 | Prozac or fluoxetine 36 | Prozac or fluoxetine 37 | Prozac or fluoxetine 38 | Prozac or fluoxetine 39 | Prozac or fluoxetine 40 | Prozac or fluoxetine 41 | Prozac or fluoxetine 42 | Prozac or fluoxetine 43 | Prozac or fluoxetine 44 | Prozac or fluoxetine 45 | Prozac or fluoxetine 46 | Prozac or fluoxetine 47 | Prozac or fluoxetine 48 | Prozac or fluoxetine 49 | Prozac or fluoxetine 50 | Prozac or fluoxetine 51 | Prozac or fluoxetine 52 | Prozac or fluoxetine 53 | Prozac or fluoxetine 54 | Prozac or fluoxetine 55 | Prozac or fluoxetine 56 | Prozac or fluoxetine 57 | Prozac or fluoxetine 58 | Prozac or fluoxetine 59 | Prozac or fluoxetine 60 | Prozac or fluoxetine 61 | Prozac or fluoxetine 62 | Prozac or fluoxetine 63 | Prozac or fluoxetine 64 | Prozac or fluoxetine 65 | Prozac or fluoxetine 66 | Prozac or fluoxetine 67 | Prozac or fluoxetine 68 | Prozac or fluoxetine 69 | Prozac or fluoxetine 70 | Prozac or fluoxetine 71 | Prozac or fluoxetine 72 | Prozac or fluoxetine 73 | Prozac or fluoxetine 74 | Prozac or fluoxetine 75 | Prozac or fluoxetine 76 | Prozac or fluoxetine 77 | Prozac or fluoxetine 78 | Prozac or fluoxetine 79 | Prozac or fluoxetine 80 | Prozac or fluoxetine 81 | Prozac or fluoxetine 82 | Prozac or fluoxetine 83



© DreamPharm.com